NGEN
NervGen Pharma Corp.
Healthcare · Biotechnology · NCM
$1.86
Data: 2026-05-15
✓ ETHICAL PASS
MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$289M
Total market value of the company
0.00
Rev Growth
0.0%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About NervGen Pharma Corp.
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
0.0% PASS
Debt must be below 33% of total assets
Cash Ratio
7.6% PASS
Interest-bearing cash below 33% of assets
Receivables
0.0% PASS
Receivables below 49% of assets
Revenue Purity
0.0% PASS
Non-compliant revenue below 5% — any excess requires purification
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
19.9%
Historical annualised return based on price data
Days in State
2
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-08 | Mckerracher (Krista L) | Director of Issuer | 10,000 | $41,910 | |
| 2026-04-02 | Mckerracher (Krista L) | Director of Issuer | 5,000 | $21,150 | |
| 2026-03-02 | Mckerracher (Krista L) | Director of Issuer | 10,000 | $38,520 | |
| 2026-02-26 | Mckerracher (Krista L) | Director of Issuer | 5,000 | $20,640 | |
| 2026-02-26 | Mckerracher (Krista L) | Director of Issuer | 5,000 | $20,515 | |
| 2026-02-20 | Mckerracher (Krista L) | Director of Issuer | 9,980 | $42,914 | |
| 2026-02-19 | Mckerracher (Krista L) | Director of Issuer | 10,000 | $41,770 | |
| 2026-02-19 | Mckerracher (Krista L) | Director of Issuer | 20 | $86 | |
| 2026-02-18 | Mckerracher (Krista L) | Director of Issuer | 10,000 | $30,170 | |
| 2026-02-12 | Mckerracher (Krista L) | Director of Issuer | 10,000 | $39,960 |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-15